Skip to main content
. 2015 Jan 8;10(1):e0115672. doi: 10.1371/journal.pone.0115672

Table 3. Results for castPCR and Therascreen for each case included in the study.

No. TheraScreen Mutation Ct TheraScreen DeltaCt Therascreen Mutation castPCR Mutation Ct castPCR Delta Ct castPCR Mutation
P1 N/A N/A WT N/A N/A WT
P2 N/A N/A WT 33.5 2.5 BRAF c.1799T>A
P3 28.4 0.5 KRAS c.35G>C N/A N/A WT
P4 31.9 0.65 KRAS c.35G>T 33.1 3.0 KRAS c.35G>T
P5 32.1 0.8 KRAS c.35G>T 35.0 4.3 KRAS c.35G>T
P6 30.7 1.35 KRAS c.35G>T 28.0 2.3 KRAS c.35G>T
P7 34.6 3.69 KRAS c.35G>A 32.5 3.5 KRAS c.35G>A
P8 N/A N/A WT N/A N/A WT
P9 N/A N/A WT N/A N/A WT
P10 N/A N/A WT 26.2 0.6 BRAF c.1799T>A
P11 34 4.12 KRAS c.38G>A 34.7, 35.3 5.4, 9.0 KRAS c.38G>A, KRAS c.182A>G
P12 31.5 3.25 KRAS c.34G>T 28.0 3.1 KRAS c.34G>T
P13 N/A N/A WT N/A N/A WT
P14 N/A N/A WT N/A N/A WT
P15 N/A N/A WT N/A N/A WT
P16 32.3 4.04 KRAS c.38G>A 29.3 4.0 KRAS c.38G>A
P17 35.1 1.02 KRAS c.35G>T 33.5 1.8 KRAS c.35G>T
P18 N/A N/A WT N/A N/A WT
P19 29.1 1.85 KRAS c.35G>T 27.1 2.8 KRAS c.35G>T
P20 N/A N/A WT N/A N/A WT
P21 32.1 2.91 KRAS c.34G>T 31.3 4.2 KRAS c.34G>T
P22 33.3 3.59 KRAS c.35G>A 33.0 3.9 KRAS c.35G>A
P23 35.9 4.14 KRAS c.38G>A 33.2 3.1 KRAS c.38G>A
P24 N/A N/A WT N/A N/A WT
P25 36.7 7.58 KRAS c.35G>C N/A N/A WT
P26 N/A N/A WT N/A N/A WT
P27 N/A N/A WT N/A N/A WT
P28 N/A N/A WT N/A N/A WT
P29 34 2.75 KRAS c.35G>A 33.4 3.6 KRAS c.35G>A
P30 N/A N/A WT N/A N/A WT
P31 37.6 3.87 KRAS c.38G>A 33.0 4.9 KRAS c.38G>A
P32 34.6 3.06 KRAS c.35G>A 38.5 7.7 KRAS c.35G>A
P33 N/A N/A WT 27.4 1.1 BRAF c.1799T>A
P34 N/A N/A WT N/A N/A WT
P35 31.6 3.88 KRAS c.34G>A 29.5 2.3 KRAS c.34G>A
P36 N/A N/A WT 37.3 8.6 BRAF c.1799T>A
P37 N/A N/A WT 29.0 2.0 BRAF c.1799T>A
P38 N/A N/A WT N/A N/A WT
P39 N/A N/A WT 36.0 9.4 BRAF c.1799T>A
P40 N/A N/A WT N/A N/A WT
P41 N/A N/A WT N/A N/A WT
P42 N/A N/A WT N/A N/A WT
P43 33.2 3.56 KRAS c.38G>A 36.9 6.5 KRAS c.38G>A
P44 N/A N/A WT N/A N/A WT
P45 28.9 1.1 KRAS c.35G>T 28.7 2.2 KRAS c.35G>T
P46 N/A N/A WT N/A N/A WT
P47 32.7 6.38 KRAS c.34G>T 30.4 4.2 KRAS c.34G>T
P48 N/A N/A WT N/A N/A WT
P49 32.4 6.97 KRAS c.35G>A 28.2 2.7 KRAS c.35G>A
P50 N/A N/A WT N/A N/A WT
P51 N/A N/A WT N/A N/A WT
P52 N/A N/A WT 39.4 9.4 KRAS c.34G>A
P53 32 4.35 KRAS c.35G>A 30.9 3.6 KRAS c.35G>A
P54 N/A N/A WT N/A N/A WT
P55 N/A N/A WT N/A N/A WT
P56 31.4 3.21 KRAS c.34G>T 30.4 3.7 KRAS c.34G>T
P57 N/A N/A WT N/A N/A WT
P58 32.5 4.04 KRAS c.35G>A 32.8 4.3 KRAS c.35G>A
P59 30 3.12 KRAS c.35G>T 29.6 4.4 KRAS c.35G>T
P60 N/A N/A WT N/A N/A WT
P61 N/A N/A WT N/A N/A WT
P62 30.1 2.73 KRAS c.34G>C 27.7, 3.89, KRAS c.34G>C
P63 N/A N/A WT N/A N/A WT
P64 N/A N/A WT N/A N/A WT
P65 N/A N/A WT N/A N/A WT
P66 N/A N/A WT 27.3 1.6 BRAF c.1799T>A
P67 31.6 3.97 KRAS c.35G>A 28.6 3.6 KRAS c.35G>A
P68 32.2 4.26 KRAS c.35G>A 30.2 4.4 KRAS c.35G>A
P69 N/A N/A WT N/A N/A WT
P70 N/A N/A WT N/A N/A WT
P71 N/A N/A WT 26.9 1.4 BRAF c.1799T>A
P72 N/A N/A WT N/A N/A WT
P73 N/A N/A WT N/A N/A WT
P74 29.5 2.16 KRAS c.34G>C 28.1 3.2 KRAS c.34G>C
P75 29.7 1.68 KRAS c.35G>T 28.5 2.5 KRAS c.35G>T
P76 30.5 2.02 KRAS c.35G>T 29.8 4.5 KRAS c.35G>T
P77 N/A N/A WT N/A N/A WT
P78 N/A N/A WT N/A N/A WT
P79 N/A N/A WT N/A N/A WT
P80 N/A N/A WT N/A N/A WT
P81 34.1 2.33 KRAS c.34G>C 33.1 4.0 KRAS c.34G>C
P82 N/A N/A WT N/A N/A WT
P83 N/A N/A WT N/A N/A WT
P84 N/A N/A WT 27.1 1.6 BRAF c.1799T>A
P85 36.6 4.58 KRAS c.38G>A 34.3 5.1 KRAS c.38G>A
N/A N/A WT 28.8 2.7 BRAF c.1799T>A
P86 30.8 2.3 KRAS c.35G>T 30.0, 35.1 4.1, 8.9 KRAS c.35G>T, BRAF c.1799T>A
P87 N/A N/A WT N/A N/A WT
P88 N/A N/A WT N/A N/A WT
P89 N/A N/A WT N/A N/A WT
N/A N/A WT N/A N/A WT
P90 N/A N/A WT 27.0 1.5 BRAF c.1799T>A
W1 27.85 2.14 KRAS c.35G>C 30.5 3.4 KRAS c.35G>C
W2 30.53 2.26 KRAS c.35G>A 29.7 2.6 KRAS c.35G>A
W3 28.57 2.86 KRAS c.34G>T 31.4 4.0 KRAS c.34G>T
W4 N/A N/A WT N/A N/A WT
W5 N/A N/A WT 28.7 1.3 BRAF c.1799T>A
W7 N/A N/A WT N/A N/A WT
W8 N/A N/A WT N/A N/A WT

Ct values for each reference gene are given with the ΔCt. An analysis matrix is used to determine the assay result (mutant or wild-type) according to thresholds defined by the manufacturer. There were three discrepant results (shown in bold): P3 showed KRAS c.35G>C by both methods on retesting, while P25 and P52 were both wild-type. Two cases (P11 and P86) showed amplification for more than one mutation. N/A, not applicable; WT, wild-type.